Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-17 of 17

Sort by

Sort Order Select

Journal Articles

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Hannah Katz, Lauren N Scott, Pilar Thangwaritorn, Jianzheng Wu, William Wesson, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi, Sunil Abhyankar, Leyla O. Shune, Muhammad Umair Mushtaq, Anurag Singh, Haitham Abdelhakim, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Liz Muenks, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5030.

https://doi.org/10.1182/blood-2024-199312

Published: 2024

Journal Articles

Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)

Sara Leidy, Jordan Snyder, James A Davis, William Wesson, Brian Hess, Ryan Jacobs, Madalyn Edmonds, Nausheen Ahmed, Marc Hoffmann

Blood (2024) 144 (Supplement 1): 2350.

https://doi.org/10.1182/blood-2024-199658

Published: 2024

Journal Articles

Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients

Blood (2024) 144 (Supplement 1): 7414.

https://doi.org/10.1182/blood-2024-206235

Published: 2024

Journal Articles

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Lauren N Scott, William Wesson, Pilar Thangwaritorn, Raeef L Rahman, Forat Lutfi, Marc Hoffmann, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 389.

https://doi.org/10.1182/blood-2024-205983

Published: 2024

Journal Articles

An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Utkarsh Goel, Danai Dima, James A Davis, Aliya Rashid, William Wesson, Shaun DeJarnette, Fauzia Ullah, Evguenia Ouchveridze, Mariam Markouli, Claire Yun Kyoung Ryu Tiger, Louis Williams, Sandra Mazzoni, Beth M. Faiman, Craig Sauter, Faiz Anwer, Shahzad Raza, Leyla O. Shune, Jack Khouri

Blood (2024) 144 (Supplement 1): 4708.

https://doi.org/10.1182/blood-2024-203984

Published: 2024

Journal Articles

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Raeef L Rahman, Jianzheng Wu, Lauren N Scott, William Wesson, Razan Mansour, Aung M. Tun, Marc Hoffmann, Al-Ola Abdallah, Dinesh Pal Mudaranthakam, Joseph P. McGuirk, Nausheen Ahmed, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7099.

https://doi.org/10.1182/blood-2024-205978

Published: 2024

Journal Articles

Axi-cel outcomes among non-Hispanic Black patients

William Wesson, Nausheen Ahmed

Blood (2024) 143 (26): 2681–2682.

https://doi.org/10.1182/blood.2024024959

Published: 2024

Journal Articles

Use of Eltrombopag for Post-CAR T Cytopenias: A Multi-Institutional Experience

William Wesson, Nausheen Ahmed, James A Davis, Mary McGann, Aliya Rashid, Carine Tabak, Emerson Logan, Jose Marchena-Burgos, Maggie Nelson, Leyla Shune, Marc S. Hoffmann, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2023-181283

Published: 2023

Journal Articles

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Aroog Khaliq, William Wesson, Emerson Logan, Carine Tabak, Aliya Rashid, Razan Mansour, Muhammad Umair Mushtaq, Joseph P McGuirk, Hamza Hashmi, Mehdi Hamadani, Al-Ola Abdallah, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 2344.

https://doi.org/10.1182/blood-2023-179409

Published: 2023

Journal Articles

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Aliya Rashid, William Wesson, Forat Lutfi, Muhammad Umair Mushtaq, Joseph P McGuirk, Al-Ola Abdallah, Wei Cui, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6801.

https://doi.org/10.1182/blood-2023-182126

Published: 2023

Journal Articles

Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma

William Wesson, Aliya Rashid, Md Saiful Islam Saif, Emerson Logan, Carine Tabak, Mary McGann, James A Davis, Liz Hazlett, Forat Lutfi, Muhammad Umair Mushtaq, Al-Ola Abdallah, Marc S. Hoffmann, Hamza Hashmi, Joseph P McGuirk, Mehdi Hamadani, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6914.

https://doi.org/10.1182/blood-2023-182872

Published: 2023

Journal Articles

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Blood (2023) 142 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2023-184345

Published: 2023

Journal Articles

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Peter A. Riedell, Miguel-Angel Perales, Richard T Maziarz, Jamie Brower, Gunjan L. Shah, Andy Chen, Olalekan O. Oluwole, Stephen J Schuster, Michael R. Bishop, Joseph P McGuirk, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 4887.

https://doi.org/10.1182/blood-2023-182837

Published: 2023

Journal Articles

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Mohammad Ahsen Soomro, Shebli Atrash, Aliya Rashid, William Wesson, Hamza Hashmi, Aimaz Afrough, Barry S. Skikne, Forat Lutfi, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6900.

https://doi.org/10.1182/blood-2023-180306

Published: 2023

Journal Articles

Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure

Forat Lutfi, Briha Ansari, Afraah Hawa, Al-Ola Abdallah, Zubair Shah, Andre Khazak, Hussam Hawamdeh, Marc S. Hoffmann, Muhammad Umair Mushtaq, William Wesson, Aliya Rashid, Maggie Nelson, Leyla Shune, Sunil Abhyankar, Joseph P McGuirk, Charles Porter, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6916.

https://doi.org/10.1182/blood-2023-188031

Published: 2023

Journal Articles

B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T ) Therapy for Multiple Myeloma

William Wesson, Wei Cui, Muhammad Mushtaq, Rajat Bansal, Anurag K. Singh, Marc Hoffmann, Aung M Tun, Ramesh Balusu, Haitham Abdelhakim, Sunil H Abhyankar, Joseph P. McGuirk, Leyla O. Shune, Al-Ola Abdallah, Nausheen Ahmed

Blood (2022) 140 (Supplement 1): 12781–12783.

https://doi.org/10.1182/blood-2022-160437

Published: 2022

Journal Articles

Eltrombopag Stimulation for Neutrophil and Platelet Recovery Following Axicabtagene Ciloleucel (axi-cel) Therapy in Lymphoma

William Wesson, Maggie Nelson, Muhammad Mushtaq, Rajat Bansal, Robert Kribs, Anurag K. Singh, Marc Hoffmann, Aung M Tun, Al-Ola Abdallah, Haitham Abdelhakim, Sunil H Abhyankar, Joseph P. McGuirk, Leyla O. Shune, Nausheen Ahmed

Blood (2022) 140 (Supplement 1): 12757–12759.

https://doi.org/10.1182/blood-2022-162433

Published: 2022

NARROW

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)

Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Axi-cel outcomes among non-Hispanic Black patients

Use of Eltrombopag for Post-CAR T Cytopenias: A Multi-Institutional Experience

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure

B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T ) Therapy for Multiple Myeloma

Eltrombopag Stimulation for Neutrophil and Platelet Recovery Following Axicabtagene Ciloleucel (axi-cel) Therapy in Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only